Background Multilevel posterior spine fusion is associated with significant intraoperative
blood loss. Tranexamic acid is an antifibrinolytic agent that reduces intraoperative blood …

Study Design. Retrospective, observational study. Objective. To assess the efficacy and
safety of tranexamic acid (TXA) in decreasing operative blood loss and the need for …

Study Design. Prospective randomized double-blinded trial Objective. The objective of this
study is to determine the efficacy of high-dose versus low-dose tranexamic acid (TXA) in …

Objective To evaluate the efficacy and safety of tranexamic acid (TXA) in patients with
adolescent idiopathic scoliosis undergoing corrective surgery. Methods A literature search of …

Background: Tranexamic acid (TXA) is an antifibrinolytic drug that reduces surgical blood
loss. Evidence supporting its efficacy in surgery for adolescent idiopathic scoliosis is not …

Background: Previous studies have demonstrated that the use of tranexamic acid (TXA)
reduces blood loss and transfusion requirements in children undergoing scoliosis surgery …

Abstract BACKGROUND CONTEXT Tranexamic acid (TXA) is widely used in surgery for
adolescent idiopathic scoliosis (AIS) and has been proved to be efficacious in reducing …

Background Tranexamic acid (TXA) has been widely used in orthopedic surgery, but its
efficacy in adolescent scoliosis (AS) surgery remains unclear in the literature. The purpose …

Purpose Intraoperative blood loss in scoliosis surgery often requires transfusions.
Autogenous blood decreases but does not eliminate risks typically associated with allogenic …

Background Many reports had been received on the application of antifibrinolytic
medications on spinal corrective surgery and the surgical outcome evaluations of its efficacy …